(S)-(+)-4-hydroxy-5,5-dimethyl-3-hexanone | 133006-31-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-(+)-4-hydroxy-5,5-dimethyl-3-hexanone
• 英文别名: (S)-4-hydroxy-5,5-dimethylhexan-3-one；(4S)-4-hydroxy-5,5-dimethylhexan-3-one
• CAS: 133006-31-2
• 化学式: C₈H₁₆O₂
• 分子量: 144.214
• InChiKey: JSLPVOWQFXBZJF-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-(+)-4-hydroxy-5,5-dimethyl-3-hexanone 在 盐酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 (1S,2S,4S)-1,4-dihydroxy-2,5,5-trimethyl-1-phenyl-3-hexanone
  参考文献：
  名称：

  Protocols for the preparation of each of the four possible stereoisomeric .alpha.-alkyl-.beta.-hydroxy carboxylic acids from a single chiral aldol reagent

  摘要：

  Protocols have been devised whereby all four possible stereoisomeric alpha-alkyl-beta-hydroxy carboxylic acids can be derived from a single aldol reagent, hydroxy ketone 3. Compound 3, obtained in enantiomerically homogeneous form in 50% overall yield from tert-butylglycine (1), is used for aldol reactions in the form of its trimethylsilyl and tert-butyldimethylsilyl derivatives, 4 and 5. The Z lithium and Z boron enolates of 4 react with various aldehydes to give aldols 8 and 9, respectively. Deprotonation of 4 by bromomagnesium 2,2,6,6-tetramethylpiperidide (MTMP) gives the E enolate, which may be trapped by trimethylsilyl chloride to obtain the E silyl enol ether 11. The E bromomagnesium enolate of 4 reacts with aldehydes to give aldols of structure 15. Transmetalation of the bromomagnesium enolate of keto ether 5 is accomplished by reaction with (triisopropoxy)titanium chloride. The resulting E (triisopropoxy)titanium enolate reacts with aldehydes to provide aldols of structure 17. The aldols resulting from the foregoing reactions are hydrolyzed to keto diols 19-22, which are oxidized to the stereoisomeric alpha-methyl-beta-hydroxy carboxylic acids 23-26.

  DOI：

  10.1021/jo00007a043
• 作为产物：
  描述：

  (S)-(-)-2-羟基-3,3-二甲基丁酸 生成 (S)-(+)-4-hydroxy-5,5-dimethyl-3-hexanone
  参考文献：
  名称：

  Protocols for the preparation of each of the four possible stereoisomeric .alpha.-alkyl-.beta.-hydroxy carboxylic acids from a single chiral aldol reagent

  摘要：

  Protocols have been devised whereby all four possible stereoisomeric alpha-alkyl-beta-hydroxy carboxylic acids can be derived from a single aldol reagent, hydroxy ketone 3. Compound 3, obtained in enantiomerically homogeneous form in 50% overall yield from tert-butylglycine (1), is used for aldol reactions in the form of its trimethylsilyl and tert-butyldimethylsilyl derivatives, 4 and 5. The Z lithium and Z boron enolates of 4 react with various aldehydes to give aldols 8 and 9, respectively. Deprotonation of 4 by bromomagnesium 2,2,6,6-tetramethylpiperidide (MTMP) gives the E enolate, which may be trapped by trimethylsilyl chloride to obtain the E silyl enol ether 11. The E bromomagnesium enolate of 4 reacts with aldehydes to give aldols of structure 15. Transmetalation of the bromomagnesium enolate of keto ether 5 is accomplished by reaction with (triisopropoxy)titanium chloride. The resulting E (triisopropoxy)titanium enolate reacts with aldehydes to provide aldols of structure 17. The aldols resulting from the foregoing reactions are hydrolyzed to keto diols 19-22, which are oxidized to the stereoisomeric alpha-methyl-beta-hydroxy carboxylic acids 23-26.

  DOI：

  10.1021/jo00007a043

文献信息

• QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS
  申请人：Gai Yonghua

  公开号：US20080267918A1

  公开（公告）日：2008-10-30

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I化合物，或其药用可接受的盐、酯或前药： 其抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含前述化合物的药物组合物，用于给患有HCV感染的对象服用。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗主体中的HCV感染的方法。
• Enzymatic Cross‐Benzoin‐Type Condensation of Aliphatic Aldehydes: Enantioselective Synthesis of 1‐Alkyl‐1‐hydroxypropan‐2‐ones and 1‐Alkyl‐1‐hydroxybutan‐2‐ones
  作者：Graziano Di Carmine、Olga Bortolini、Alessandro Massi、Michael Müller、Giovanni Bernacchia、Giancarlo Fantin、Daniele Ragno、Pier Paolo Giovannini

  DOI：10.1002/adsc.201800357

  日期：2018.11.5

  with high conversions (89–99%) and in good to high enantiomeric excess (72–99% ee). In a similar way, high conversions (75–99%) and good ee (76–99%) were observed in reactions performed with the same set of aldehyde acceptors, but using 4‐hydroxy‐4‐methylhexan‐3‐one as propionyl anion donor. This is the first time that most of the products described herein have been prepared via benzoin‐type condensation

  苯甲素类反应已被广泛用作制备α的合成策略-羟基酮。硫胺二磷酸（ThDP）依赖性酶是此类反应类型的不对称形式的出色催化剂。特别是，在芳族反应物的交叉安息香缩合和芳族/脂肪族混合反应中，这些酶的使用导致了高水平的化学，区域和立体选择性。目前的工作证实了脂族反应物的这一趋势，概述了由ThDP依赖性乙酰丙酮：二氯苯酚吲哚酚氧化还原酶（Ao： DCPIP OR）。在这些反应中，使用3-羟基-3-甲基丁-2-酮（甲基乙酰丁）作为活化的乙醛供体，而4-羟基-4-甲基己基-3-酮是首次用作活化丙醛的前体。除了3-羟基戊烷-2-酮和3-羟基己酮-2-酮分别通过甲基乙酰丙酮分别与丙醛和丁醛缩合而得到外消旋形式外，所有其他产物均是通过使用同一供体进行反应而获得的较高的转化率（89–99％）和对映异构体过量至较高的对映体（72–99％）获得了具有更多受阻醛受体的化合物ee）。以类似的方式，在使用相同的一组醛受体但
• VAN, DRAANEN NANINE A.;ARSENIYADIS, SIMEON;CRIMMINS, MICHAEL T.;HEATHCOCK+, J. ORG. CHEM., 56,(1991) N, C. 2499-2506
  作者：VAN, DRAANEN NANINE A.、ARSENIYADIS, SIMEON、CRIMMINS, MICHAEL T.、HEATHCOCK+

  DOI：——

  日期：——
• OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080292587A1

  公开（公告）日：2008-11-27

  The present invention discloses compounds of formulae I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US7511157B2
  申请人：——

  公开号：US7511157B2

  公开（公告）日：2009-03-31